CureVac N.V. (ETR:5CV)
Germany flag Germany · Delayed Price · Currency is EUR
4.718
+0.002 (0.04%)
Aug 15, 2025, 5:35 PM CET

CureVac Company Description

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy.

It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane.

In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics.

Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E.

coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer.

Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma.

CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

CureVac N.V.
CountryNetherlands
Founded2000
IndustryBiotechnology
SectorHealthcare
Employees983
CEOAlexander Zehnder

Contact Details

Address:
Friedrich-Miescher-Strasse 15
Tübingen, 72076
Germany
Phone49 7071 9883 0
Websitecurevac.com

Stock Details

Ticker Symbol5CV
ExchangeDeutsche Börse Xetra
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberNL0015436031
SIC Code2836

Key Executives

NamePosition
Dr. Alexander Zehnder M.B.A., M.D.Chief Executive Officer, MD and Member of Management Board
Axel-Sven MalkomesChief Financial Officer and Member of Executive Board
Dr. Malte Greune Ph.D.Chief Operating Officer, Member of Management Board and MD
Dr. Myriam Mendila M.D.Chief Scientific Officer, Head of Research & Development, MD and Member of the Management Board
Thaminda RamanayakeChief Business Officer and Member of Executive Board
Dr. Sarah FakihVice President of Corporate Communications and Investor Relations
Marco Rau L.L.M., Ph.D.General Counsel
Slavica Stevanovic-HeckHead of Human Resources
Dr. Ulrike Gnad-Vogt M.D., Ph.D.Senior Vice President and Area Head of Oncology
Dr. Patrick BaumhofSenior Vice President of Technology